Last reviewed · How we verify
LPV/r
LPV/r is a combination of lopinavir and ritonavir that inhibits HIV protease, preventing the maturation of HIV virions and blocking viral replication.
LPV/r is a combination of lopinavir and ritonavir that inhibits HIV protease, preventing the maturation of HIV virions and blocking viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection in pregnant women.
At a glance
| Generic name | LPV/r |
|---|---|
| Also known as | Ritonavir-boosted lopinavir, Daily LPV/r, Kaletra |
| Sponsor | The HIV Netherlands Australia Thailand Research Collaboration |
| Drug class | Protease inhibitor (PI) combination |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Lopinavir is a protease inhibitor that binds to HIV protease and prevents the cleavage of viral polyproteins necessary for infectious particle formation. Ritonavir is a potent CYP3A4 inhibitor included as a pharmacokinetic booster to increase lopinavir plasma concentrations and half-life, allowing for lower and less frequent dosing. Together, LPV/r suppresses HIV viral load and restores CD4+ T-cell counts in infected patients.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 infection in pregnant women
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Elevated cholesterol/triglycerides
- Elevated liver enzymes
- Headache
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Bone and Body Comp: A Sub Study of the SECOND-LINE Study (PHASE4)
- A Prospective Cohort of Children With HIV Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LPV/r CI brief — competitive landscape report
- LPV/r updates RSS · CI watch RSS
- The HIV Netherlands Australia Thailand Research Collaboration portfolio CI